勘误：靶向肿瘤MUC1糖蛋白的嵌合抗原受体T细胞可降低三阴性乳腺癌的生长。
Corrigendum: CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth.
作者信息
Zhou Ru, Yazdanifar Mahboubeh, Roy Lopamudra Das, Whilding Lynsey M, Gavrill Artemis, Maher John, Mukherjee Pinku
机构信息
Department of Biological Sciences, University of North Carolina at Charlotte, Charlotte, NC, United States.
School of Cancer and Pharmaceutical Sciences, King's College London, Guy's Hospital Campus, London, United Kingdom.
出版信息
Front Immunol. 2020 Dec 7;11:628776. doi: 10.3389/fimmu.2020.628776. eCollection 2020.
Abstract
[This corrects the article DOI: 10.3389/fimmu.2019.01149.].
摘要
[本文更正了文章DOI：10.3389/fimmu.2019.01149。]
相似文献
1
Corrigendum: CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth.勘误：靶向肿瘤MUC1糖蛋白的嵌合抗原受体T细胞可降低三阴性乳腺癌的生长。
Front Immunol. 2020 Dec 7;11:628776. doi: 10.3389/fimmu.2020.628776. eCollection 2020.
2
CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth.嵌合抗原受体 T 细胞靶向肿瘤 MUC1 糖蛋白可减少三阴性乳腺癌的生长。
Front Immunol. 2019 May 24;10:1149. doi: 10.3389/fimmu.2019.01149. eCollection 2019.
3
Corrigendum: Lymphocytes in Cellular Therapy: Functional Regulation of CAR T Cells.勘误：细胞治疗中的淋巴细胞：CAR-T细胞的功能调节
Front Immunol. 2019 Mar 8;10:401. doi: 10.3389/fimmu.2019.00401. eCollection 2019.
4
Combining the Specific Anti-MUC1 Antibody TAB004 and Lip-MSA-IL-2 Limits Pancreatic Cancer Progression in Immune Competent Murine Models of Pancreatic Ductal Adenocarcinoma.将特异性抗MUC1抗体TAB004与脂质体包裹的多聚谷氨酸-IL-2相结合可限制免疫健全的胰腺导管腺癌小鼠模型中的胰腺癌进展。
Front Oncol. 2019 Apr 30;9:330. doi: 10.3389/fonc.2019.00330. eCollection 2019.
5
Corrigendum: Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications.勘误：实体瘤中的嵌合抗原受体T细胞疗法：挑战与临床应用
Front Immunol. 2019 Apr 17;10:780. doi: 10.3389/fimmu.2019.00780. eCollection 2019.
6
CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation.嵌合抗原受体 T 细胞疗法治疗乳腺癌：利用肿瘤微环境驱动 T 细胞激活。
J Immunother Cancer. 2018 May 10;6(1):34. doi: 10.1186/s40425-018-0347-5.
7
PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells.非小细胞肺癌中的PSCA和MUC1作为嵌合抗原受体T细胞的靶点
Oncoimmunology. 2017 Feb 6;6(3):e1284722. doi: 10.1080/2162402X.2017.1284722. eCollection 2017.
8
Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells.一项 I 期临床试验表明，经修饰的抗 MUC1 嵌合抗原受体转导 T 细胞可有效清除 MUC1 阳性转移性精囊癌细胞。
Sci China Life Sci. 2016 Apr;59(4):386-97. doi: 10.1007/s11427-016-5024-7. Epub 2016 Mar 7.
9
Corrigendum: Advances in CAR T-cell therapy in bile duct, pancreatic, and gastric cancers.勘误：胆管癌、胰腺癌和胃癌中CAR T细胞疗法的进展
Front Immunol. 2022 Dec 20;13:1082984. doi: 10.3389/fimmu.2022.1082984. eCollection 2022.
10
Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells.使用体外自我富集、共刺激 NKG2D CAR T 细胞控制三阴性乳腺癌。
J Hematol Oncol. 2018 Jul 6;11(1):92. doi: 10.1186/s13045-018-0635-z.
引用本文的文献
1
Immunotherapy in Breast Cancer: Beyond Immune Checkpoint Inhibitors.乳腺癌的免疫治疗：超越免疫检查点抑制剂
Int J Mol Sci. 2025 Apr 21;26(8):3920. doi: 10.3390/ijms26083920.
2
Advances and challenges in CAR-T cell therapy for head and neck squamous cell carcinoma.头颈部鳞状细胞癌的嵌合抗原受体T细胞（CAR-T）疗法的进展与挑战
Biomark Res. 2025 May 1;13(1):69. doi: 10.1186/s40364-025-00783-1.
3
Analysis of the potential biological significance of glycosylation in triple-negative breast cancer on patient prognosis.三阴性乳腺癌中糖基化对患者预后潜在生物学意义的分析。
Am J Transl Res. 2024 Jun 15;16(6):2212-2232. doi: 10.62347/PXAR3644. eCollection 2024.
4
Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer.嵌合抗原受体 T 细胞疗法在头颈部癌症中的最新进展和未来展望。
Front Immunol. 2023 Jun 29;14:1213716. doi: 10.3389/fimmu.2023.1213716. eCollection 2023.
5
Nanomaterial-assisted CRISPR gene-engineering - A hallmark for triple-negative breast cancer therapeutics advancement.纳米材料辅助的CRISPR基因工程——三阴性乳腺癌治疗进展的一个标志。
Mater Today Bio. 2022 Oct 4;16:100450. doi: 10.1016/j.mtbio.2022.100450. eCollection 2022 Dec.
6
CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a sweet success?针对肿瘤特异性抗原糖型的嵌合抗原受体 T 细胞：低聚糖抗原能保证成功吗？
Front Med. 2022 Jun;16(3):322-338. doi: 10.1007/s11684-021-0901-2. Epub 2022 Jun 10.
Zotero 插件